Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia - PubMed (original) (raw)
Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia
D T Dexter et al. Brain. 1991 Aug.
Abstract
Levels of iron, copper, zinc and manganese were measured by inductively coupled plasma spectroscopy in frozen postmortem brain tissue from patients with Parkinson's disease (PD), progressive supranuclear palsy (PSP), multiple system atrophy with strionigral degeneration (MSA), and Huntington's disease (HD) compared with control subjects. Total iron levels were found to be elevated in the areas of basal ganglia showing pathological change in these disorders. In particular, total iron content was increased in substantia nigra in PD, PSP and MSA, but not in HD. Total iron levels in the striatum (putamen and/or caudate nucleus) were increased in PSP, MSA and HD but not in PD. Total iron levels were decreased in the globus pallidus in PD. There were no consistent alterations of manganese levels in basal ganglia structures in any of the diseases studied. Copper levels were decreased in the substantia nigra in PD, and in the cerebellum in PSP, and were elevated in the putamen and possibly substantia nigra in HD. Zinc levels were only increased in PD, in substantia nigra and in caudate nucleus and lateral putamen. Levels of the iron binding protein ferritin were measured in the same patient groups using a radio-immunoassay technique. Increased iron levels in basal ganglia were generally associated with normal or elevated levels of ferritin immunoreactivity, for example, the substantia nigra in PSP and possibly MSA, and in putamen in MSA. The exception was PD where there was a generalized reduction in brain ferritin immunoreactivity, even in the substantia nigra. An increase in total iron content appears to be a response to neurodegeneration in affected basal ganglia regions in a number of movement disorders. However, only in PD was there an increased total iron level, decreased ferritin content, decreased copper content, and an increased zinc concentration in substantia nigra. These findings suggest an alteration of iron handling in the substantia nigra in PD. Depending on the form in which the excess iron load exists in nigra in PD, it may contribute to the neurodegenerative process.
Similar articles
- Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia.
Sian J, Dexter DT, Lees AJ, Daniel S, Agid Y, Javoy-Agid F, Jenner P, Marsden CD. Sian J, et al. Ann Neurol. 1994 Sep;36(3):348-55. doi: 10.1002/ana.410360305. Ann Neurol. 1994. PMID: 8080242 - Topographical differences of brain iron deposition between progressive supranuclear palsy and parkinsonian variant multiple system atrophy.
Han YH, Lee JH, Kang BM, Mun CW, Baik SK, Shin YI, Park KH. Han YH, et al. J Neurol Sci. 2013 Feb 15;325(1-2):29-35. doi: 10.1016/j.jns.2012.11.009. Epub 2012 Dec 20. J Neurol Sci. 2013. PMID: 23260321 - Free-water imaging in Parkinson's disease and atypical parkinsonism.
Planetta PJ, Ofori E, Pasternak O, Burciu RG, Shukla P, DeSimone JC, Okun MS, McFarland NR, Vaillancourt DE. Planetta PJ, et al. Brain. 2016 Feb;139(Pt 2):495-508. doi: 10.1093/brain/awv361. Epub 2015 Dec 24. Brain. 2016. PMID: 26705348 Free PMC article. - Brain monoamines in progressive supranuclear palsy--comparison with idiopathic Parkinson's disease.
Hornykiewicz O, Shannak K. Hornykiewicz O, et al. J Neural Transm Suppl. 1994;42:219-27. doi: 10.1007/978-3-7091-6641-3_17. J Neural Transm Suppl. 1994. PMID: 7964689 Review.
Cited by
- Neuroimaging Biomarkers in Parkinson's Disease.
Holmes S, Tinaz S. Holmes S, et al. Adv Neurobiol. 2024;40:617-663. doi: 10.1007/978-3-031-69491-2_21. Adv Neurobiol. 2024. PMID: 39562459 Review. - Iron homeostasis and ferroptosis in human diseases: mechanisms and therapeutic prospects.
Ru Q, Li Y, Chen L, Wu Y, Min J, Wang F. Ru Q, et al. Signal Transduct Target Ther. 2024 Oct 14;9(1):271. doi: 10.1038/s41392-024-01969-z. Signal Transduct Target Ther. 2024. PMID: 39396974 Free PMC article. Review. - Postencephalitic Parkinsonism: Unique Pathological and Clinical Features-Preliminary Data.
Strobel S, Sian-Hulsmann J, Tappe D, Jellinger K, Riederer P, Monoranu CM. Strobel S, et al. Cells. 2024 Sep 10;13(18):1511. doi: 10.3390/cells13181511. Cells. 2024. PMID: 39329695 Free PMC article. - A novel NIR fluorescent probe for copper(ii) imaging in Parkinson's disease mouse brain.
Chen J, Luo R, Li S, Shao J, Wang T, Xie S, Xu L, You Q, Feng S, Feng G. Chen J, et al. Chem Sci. 2024 Jul 22;15(32):13082-13089. doi: 10.1039/d4sc03445g. eCollection 2024 Aug 14. Chem Sci. 2024. PMID: 39148792 Free PMC article. - NOX2-TRPM2 coupling promotes Zn2+ inhibition of complex III to exacerbate ROS production in a cellular model of Parkinson's disease.
AlAhmad M, Isbea H, Shitaw E, Li F, Sivaprasadarao A. AlAhmad M, et al. Sci Rep. 2024 Aug 8;14(1):18431. doi: 10.1038/s41598-024-66630-9. Sci Rep. 2024. PMID: 39117781 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous